46 results about "Tricine" patented technology

The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to fill-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

The invention relates to compositions and methods for cleaning integrated circuit substrates. The compositions are in the form of an aqueous solution and include a quaternary ammonium hydroxide compound and a chelating compound. The chelating compound includes either boric acid or at least one N-substituted aminocarboxylate selected from the group consisting of N-bis(2-hydroxyethyl)glycine(bicine), N-tris(hydroxymethyl)methyl glycine (tricine) and mixtures thereof, and can optionally include glycine, Iminodiacetic acid (IDA), Nitrilo trizacetic acid (NTA), Ethylenediammine Tetraacetic acid (EDTA), or mixtures thereof.

The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

The invention discloses a labeled 99mTc hydrazino-nicotinamide-dioxodecoyl-folic acid coordination compound with a general formula of 99mTc(HYNIC-NOON-FA)(Tricine)(L). In the structural formula, L is triphenyl sodium phosphate or triphenyl sodium photrisulfonic acid, wherein 1,8-diamido-3,6-octane dioxide is used as a connecting chain for generating a hydrazino-nicotinamide-3,6-dioxodecoyl-folic acid coupler respectively with folic acid and hydrazino-niacin through amido bonds and coordinating with oxygen atoms and phosphorus atoms in a co-ligand Tricine and an L molecule and 99mTc, and the 99mTc(HYNIC-NOON-FA)(Tricine)(L) coordination compound is obtained through two steps of: (a) synthesizing the hydrazino-nicotinamide-3,6-dioxodecoyl-folic acid coupler used as a ligand; and (b) labeling the 99mTc-hydrazino-nicotinamide-dioxodecoyl-folic acid coordination compound. The coordination compound has the advantages of high radiochemical purity, good stability, high tumor intake, good retention, low non-target organ background and clear tumor SPECT (Single Photon Emission Computed Tomography) development and can be prepared into a novel 99mTc labeled folic acid receptor tumor developer widely applied to the technical field of radioactive pharmaceutical chemistry and nuclear medicine.

The application identifies fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

A composition and associated method for chemical mechanical planarization (or other polishing) are described. The composition comprises an abrasive and a tricine-type or bicine-type compound. The composition possesses high selectivities for removal of copper in relation to tantalum and dielectric materials whilst minimizing local dishing and erosion effects in CMP. The composition may further comprise an oxidizing agent in which case the composition is particularly useful in conjunction with the associated method for metal CMP applications (e.g., copper CMP).

The invention provides nucleic acid preserving fluid. The nucleic acid preserving fluid consists of a nuclease inhibitor, a protein denaturant, a stabilizer, a bacteriostatic agent and a Tricine buffer solution, wherein the concentration of the nuclease inhibitor is 5mg / ml-20mg / ml, the concentration of the protein denaturant is 20mg / ml-80mg / ml, the concentration of the stabilizer is 30mg / ml-90mg / ml, the concentration of the bacteriostatic agent is 100mg / ml-500mg / ml, and the concentration of the Tricine buffer solution is 20nM-120nM. The nucleic acid preserving fluid has the beneficial effectsthat the nucleic acid preserving fluid is capable of effectively preventing degradation of nucleic acid at a normal temperature and providing a stable environment for nucleic acid, so that the preservation time of the nucleic acid is prolonged, and the safety during collection, transportation and detection can be guaranteed; and meanwhile, pathogenic microorganisms can be inactivated, and the nucleic acid preserving fluid has the advantages of low preparation cost, stable performance, easiness in preservation and the like.

The invention discloses a compound with a general formula of 99mTc (HYNIC-FAPI) (tricine / TPPTS) technetium-99 m labeled FAPI derivative containing hydrazino-nicotinamide, and a preparation method and application thereof. By two steps of synthesis of ligand HYNIC-FAPI and 99mtc (HYNIC-FAPI) (tricine / TPPTS) preparation, the 99mTc (HYNIC-FAPI) (tricine / TPPTS) complex is obtained. The complex has the advantages of simple preparation, high radiochemical purity and good stability, has high uptake and good detention at tumor parts of tumor-bearing mice, has specific uptake in tumors, and is a novel tumor radiopharmaceutical with clinical application value.

The invention discloses a 99mTc labeled hydrazinonicotinamide group-pteroyllysine coordination compound with an expression of 99mTc (HYNIC-Lys-Pteroyl)(Tricine)(TPPTS), a preparation method and application. The target coordination compound is obtained through the following two steps of: (a) synthesizing pteroyllysine 6-(2-N,N-dimethylbenzaldehydehydrazono) niacin as a ligand; and (b) obtaining the 99mTc labeled hydrazinonicotinamide group-pteroyllysine coordination compound. The coordination compound has the advantages of high radiochemical purity, good stability, low price, high tumor uptakerate, good retention and good target / non-target specific values of tumor / blood, tumor / muscle, and the like and can be popularized and applied by being used as a novel 99mTc labeled folate receptor tumor image developer.

A process for the capture of CO2 from gas streams comprising contacting a CO2 containing gas stream with an aqueous alkanolamine solution, wherein the alkanolamine is selected from the group consisting of: 3-piperidinemethanol, Tricine, 3-quinuclidinol, 3-piperidino-1,2-propanediol and their salts.

A MRI molecular image probe with high biologic performance and low cost is composed of central ion, specific molecule and chelating agent consisting of primary chelating agent chosen from HYNIC and secondary one chosen from Tricine and EDDA. Its preparing process is also disclosed.

Turbidimetric immunoassay of insoluble carrier particles that can inhibit the agglutination reaction of insoluble carrier particles such as latex by inhibiting the effect of plasma components that affect the measured value, stabilize the agglutination reaction, stabilize the absorbance of the reaction solution, and obtain accurate measurement results A reagent for measurement, a kit for insoluble carrier particle turbidimetric immunoassay, and a method for insoluble carrier particle turbidimetric immunoassay using the reagent or kit. In the presence or absence of a buffer containing a compound containing the following groups in the molecule, such as broad bean pyrimidine glucoside, tricoflavone, etc., the insoluble carrier particles are loaded with antibodies or antigens, and then, in the presence of the above buffer , the insoluble carrier particle suspension sensitive to the antibody or antigen is in contact with the test body, and an immunoagglutination reaction occurs, and the concentration produced is measured through the agglutination reaction of the insoluble carrier particles, and the antigen or antibody in the test body is quantified. (In the formula, R1, R2, and R3 can be the same or different, and represent a hydrogen atom, a hydroxyalkyl group, etc.)

The invention discloses pichia pastoris gene engineering bacteria for recombinant expression of human glutamic acid decarboxylase and belongs to the technical field of gene engineering. A human glutamic acid decarboxylase gene GAD65 and a vector pPICZalpha are connected to establish an expression vector pPICZalpha-hGAD65 which is placed in pichia pastoris X-33 in an electricity facing mode, and a recombinant strain for excessively expressing human glutamic acid decarboxylase (GAD65) is obtained. Through shake flask fermentation, Tricine-SDS-PAGE and Western Blot identification on the recombinant strain, it is proved that human glutamic acid decarboxylase (GAD65) achieves inducible expression, fusion protein is obtained after ferementaiton supernate is separated and purified, and the concentration of protein hGAD65 reaches 2.36 g / L through measurement on the protein concentration.

A chicken intestinal tract Beta-defensin cDNA is characterized in that the cDNA has the following sequence: tcagacagcc agctgtgcag gaacaaccat ggccactgcc ggaggctctg cttccacatg gagagctggg ctgggagctg catgaacggc cgcctgcgct gctgcaggtt ctccaccaag cagccctttt ccaaccctaa acattcagtg ctgcacacag cagagcagga cccttcccca agccttggag ggacgtga. The amino acid sequence of the Beta-defensin is Ser-Asp-Ser-Gln-Leu Cys-Arg-Asn-Asn-His Gly-His-Cys-Arg- Arg Leu-Cys-Phe-His-Met Glu- Ser-Trp-Ala-Gly Ser-Cys-Met-Asn-Gly Arg-Leu-Arg-Cys-Cys Arg-Phe-Ser-Thr-Lys-Gln Pro-Phe-Ser-Asn-Pro Lys-His-Ser-Val-Leu His-Thr-Ala-Glu-Gln Asp-Pro-Ser-Pro-Ser Leu-Gly-Gly-Thr. The extraction method comprises the following steps of: (1) collecting broken mucosa cells of chicken intestinal tract; (2) breaking vesicles; (3) leaching with 5% acetic acid under stirring, centrifuging, collecting supernatant, removing sediment, subpackaging the supernatant and freeze-storing to obtain crude chicken intestinal tract Beta-defensin; (4) separating the supernatant with Sephadex G-100 gel column at low temperature, eluting with 0.2mol / L sodium acetate (constant flow pump speed 3*1), detecting with nucleic acid-protein detector, collecting the eluate with an automatic collector (1.5mL each tube), and recording with a recorder (speed 6cm / h, and range 20mV); (5) detecting the antibacterial activity of the liquid in each tube to Pasteurella with agarose diffusion method, collecting the eluate with bacteriostatic activity, and storing under vacuum freeze drying; (6) purifying the the eluate with bacteriostatic activity with Tricine-PAGE, PVDF membrane blotting the protein bands, and performing amino acid sequence analysis with Sanger partial hydrolysis method; and (7) deriving chicken intestinal tract Beta-defensin cDNA with BLAST software.

The invention discloses a 99mTc (HYNICNM) (tricine / TPPTS) complex and a preparation method and application thereof. The 99mTc (HYNICNM) (tricine / TPPTS) complex is obtained through two steps of synthesis of a ligand HYNICNM and preparation of a 99mTc (HYNICNM) (tricine / TPPTS) complex. The complex is simple and convenient to prepare and has oxygen deficiency selectivity. Tumor-bearing mice have highuptake and good retention in tumor parts, the tumor / non-target ratio is high, the uptake of non-target organs such as the liver and intestines is obviously reduced, and the 99mTc (HYNICNM) (tricine / TPPTS) complex is a novel tumor hypoxia imaging agent with excellent performance.

The invention belongs to the technical field of protein polyacrylamide gel electrophoresis, and especially relates to a polyacrylamide gel for small molecular weight protein separation. The polyacrylamide gel comprises acrylamide, N, N-methylene bisacrylamide, ultrapure water, a gel buffer solution, glycerin, an ammonium persulfate solution and tetramethylethylenediamine; the gel buffer solution comprises boric acid and a Tris-HCl solution, and the pH value of the gel buffer solution is 7.0. The polyacrylamide gel is prepared by taking Tris-boric acid as a buffer system; small molecular proteins can be well separated; protein strips are clear and sharp; the separation effect is equivalent to that of currently common small molecular protein separation gel Tris-Tricine polyacrylamide gel; the separation effect is even better than that of Tris-Tricine; the use cost of reagents is greatly reduced; and a better separation effect can be obtained.

The use of organic buffers to enhance the antimicrobial activity of aqueous pharmaceutical compositions is described. The buffers have tri-hydroxy functional groups and terminal acid groups, and are zwitterionic at physiological pH conditions. The most preferred buffer is tricine. The invention is particularly directed to the use of tricine to enhance the antimicrobial activity of ophthalmic compositions, such as solutions for disinfecting contact lenses and artificial tear compositions.

The invention discloses a preparation method of anti-aging whey protein peptide, belonging to the technical field of bioactive peptide. The preparation method comprises the following steps: hydrolyzing whey protein concentrate (WPC 80) by adopting alkaline protease, by adopting the degree of hydrolysis and the DPPH free radical scavenging rate as the indexes of evaluation, the hydrolysis and the DPPH free radical scavenging rate as the indexes, adjusting the influences of the following conditions on the hydrolysis effect: the enzyme dosage: 400-10000 U / g, the pH: 8.0, 8.5 and 9.0, the temperatures: 55 DEG C, 60 DEG C and 65 DEG C, the concentration of the substrate: 3-7 %, and the hydrolysis time: 1-6 h, thus the optimal hydrolysis process is obtained, and then enzymolysis is carried out according to the optimal process; hydrolyzing the whey protein concentrate (WPC 80) under the optimal process conditions, desalting the whey protein zymolyte by adopting DA201-C macroporous resin, carrying out dynamic desalting experiment under the following conditions: deionized water and 40-70 % alcohol are adopted as desorption reagents, the sample loading flow rate is 0.5-2.5 mL / min, and the sample loading concentration is 10-50 mg / mL, collecting peptide liquid obtained after desalting, carrying out ultra-filtration separation, and identifying the molecular weight of whey protein peptide byadopting Tricine-SDS-PAGE electrophoresis.

The invention provides a method for improving the content of peanut secretory peptide of peanut hairy roots, and belongs to the field of genetic engineering. A secretory peptide gene is cloned from peanut, a plant gene expression vector is constructed, the peanut hairy roots containing the peanut secretory peptide gene are obtained by an agrobacterium rhizogenes mediated method, the expression ofthe peanut secretory peptide gene in the transgenic peanut hairy roots is identified, the biomass of the peanut hairy roots is determined, the expression level of the peanut secretory peptide is determined by a Tricine SDS-PAGE method, and the content of the peanut secretory peptide is determined by a BCA protein quantitative detection method. The method adopts the peanut hairy root system to produce the peanut secretory peptide, has the advantages of simple operation, short cycle, high output, low cost, biological activity and the like, and is a relatively economic and efficient preparation method of the peanut secretory peptide.

The invention discloses a 99mTc-labelled hydrazino-nicotinamide-5-aminopentanoic acid-pteroyl lysine complex having an expression of 99mTc(HYNIC-penta-lys-Pteroyl) (Tricine / TPPTS), as well as a preparation method and an application, wherein the target complex is obtained by preparation comprising the following two steps: step a, synthesising a ligand, namely, pteroyl lysine-5-aminopentanoic acid-6-(2-N,N-dimethyl benzaldehyde hydrazono) nicotinic acid; and step b, preparing the 99mTc-labelled hydrazino-nicotinamide-5-aminopentanoic acid-pteroyl lysine complex. The complex has the advantages of being high in radiochemical purity, good in stability, low in price, high in tumour uptake, good in retention, and high in target / non-target ratios such as tumour / blood ratio and tumour / liver ratio, and can be popularized and applied as a novel 99mTc-labelled folate receptor tumour developer.

A process for the capture of CO2 from gas streams comprising contacting a CO2 containing gas stream with an aqueous alkanolamine solution, wherein the alkanolamine is selected from the group consisting of: 3-piperidinemethanol, Tricine, 3-quinuclidinol, 3-piperidino-1,2-propanediol and their salts.

The invention discloses a <99m>Tc(HYNICPBB)(tricine / TPPTS) complex as well as a preparation method and an application. The <99m>Tc(HYNICPBB)(tricine / TPPTS) complex is obtained through two steps including synthesis of a ligand HYNICPBB and preparation of <99m>Tc(HYNICPBB)(tricine / TPPTS). The complex is simple to prepare, high in radiochemical purity and good in stability, has better water solubility and has certain uptake in MCF-7 cells, the uptake can be significantly inhibited by palbociclib, which indicates that the complex has a CDK4 / 6 specificity. The complex has higher uptake and retention and better tumor / muscle ratios at tumor parts of female Balb / c nude mice carrying MCF-7 tumor, has obviously reduced uptake of non-target organs such as liver and can be applied to preparation of anovel CDK4 / 6 targeting tumor developer.

The invention discloses an evaluation method of specificity removal effect of haze sensitive protein in yellow wine, belonging to the field of yellow wine production process. The method comprises the steps of adding a clarifying agent into the yellow wine, collecting protein adsorbed by the clarifying agent, comparing the distribution of molecular weights of haze sensitive protein and protein adsorbed by the clarifying agent by use of the Tricine-SDS-PAGE (Tricine-sodium dodecyl sulfate-polyacrylamide gelelectrophoresis) technology, identifying the types of the haze sensitive protein and the protein adsorbed by the clarifying agent by the MALDI-TOF / TOF MS (Matrix-Assisted Laser Desorption / Ionization Time of Flight Mass) technology, measuring the total nitrogen content of the yellow wine body before and after the treatment of the clarifying agent by use of a kjeldah method finally, and evaluating that whether the haze sensitive protein is removed and evaluating the removal effect strength according to the identification result that whether the protein adsorbed by the clarifying agent is consistent to the haze sensitive protein by the MALDI-TOF / TOF MS technology and the reduction amount of the protein in the wine body by the kjeldah method. The method can directly and accurately evaluate the removal effect of the clarifying agent on the haze sensitive protein.

The invention discloses a technetium-99m labeled FAPI derivative containing D-proline glycine polypeptide modification and a preparation method and application of the technetium-99m labeled FAPI derivative containing D-proline glycine polypeptide modification, wherein the structural general formula of the technetium-99m labeled FAPI derivative is 99mTc (HYNIC-PGn-FAPI) (Tricine / TPPTS). The < 99m > Tc (HYNIC-PGn-FAP) (trickine / TPPTS) complex is prepared by the following two steps: synthesis of a ligand HYNIC-PGn-FAPI and preparation of the < 99m > Tc (HYNIC-PGn-FAP) (trickine / TPPTS), and the < 99m > Tc (HYNIC-PGn-FAP) (trickine / TPPTS) complex is obtained. The complex is simple and convenient to prepare, high in radiochemical purity and good in stability, has very high uptake and target-to-non-target ratio at the tumor site of a U87MG tumor-bearing mouse, has specific binding with FAP in tumors, and is a novel tumor radiopharmaceutical with clinical application value.

The invention relates to the technical field of in-vitro diagnosis, in particular to a gene polymorphism detection primer, probe and kit. A gene polymorphism detection reagent provided by the invention comprises a reaction solution 1 and a reaction solution 2. The PCR reaction solution 1 comprises water, DNTP, DNA polymerase, UDG enzyme, Tween, DMSO, potassium acetate, NaN3, ammonium sulfate, glycerinum and Tricine; and the PCR reaction solution 2 comprises water, manganese acetate and NaN3. The reaction solution 1 can further comprise the primer and the probe. The components are reasonable incomposition, so that the reaction solutions provided by the invention can be stably stored at 2-8 DEG C, a sample can still be well detected after the reaction solutions are placed for 6 months, andunfreezing is not needed before reaction.

Modified western blot membranes with silver nanoparticle allow the small peptides of the NS1 protein of the poultry influenza virus to be kept in the membrane and not to diffuse during transferring from the Tricine SDS PAGE. These peptides may differentiate infected from vaccinated poultry.